Pharmaq AS
ASActiveOrg 886953402Industrivegen 50, 7863 OverhallaManufacture of pharmaceutical preparations· NACE 2120Est. 2004 · 22 years old297 employeeshttps://www.pharmaq.no
Loading company…
Overview
Pharmaq AS is a Norwegian AS based in Overhalla, operating in the Manufacture of pharmaceutical preparations sector. Incorporated in 2004, the company has 297 employees and reported revenue of NOK 2.6bn in its latest annual filing.
Revenue 2025
2.6B NOK
+29% vs 2024
EBITDA margin
68.8 %
+49% vs 2024
Net profit 2025
1.5B NOK
+54% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
89.6 %
Very strongAmong the 20% highest rated companies in the industry
20212025
Liquidity ratioCurrent assets ÷ Short-term debt
9.0×
Very strongAmong the 20% highest rated companies in the industry
20212025
Return on assets (ROA)Net profit ÷ Total assets × 100
22.0 %
Very strongAmong the 20% highest rated companies in the industry
20212025
EBITDA — year on year
NOK millionsKey figures
Annual report 2025| Revenue | 2.6B NOK | +29% |
| EBITDA | 1.8B NOK | +49% |
| Net profit | 1.5B NOK | +54% |
| Total assets | 6.6B NOK | +32% |
| Equity | 5.9B NOK | +33% |
| Employees | 297 | — |
Company information
Legal name
PHARMAQ AS
Org number
886953402
Legal form
Aksjeselskap
NACE code
Founded
27 May 2004 · 22 years
Share capital
NOK 17,166,700
Employees
297 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Trine astrid vatle
Company purpose
Produksjon og salg av veterinærfarmasøytiske produkter, handel, ervervelse og drift av faste eiendommer og utnyttelse av naturforekomster, finansieringsvirksomhet, samt annen virksomhet i forbindelse med slike formål. Selskapet kan ved aksjetegning eller på annen måte, herunder ved långivning, interessere seg i andre foretagender med samme eller lignende formål.
(no translation available)
Contact
Address
Industrivegen 50, 7863 Overhalla
Phone
+47 23 29 85 00
Email
customer.service
Website
https://www.pharmaq.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), Pharmaq AS reported revenue of NOK 2.6bn, an increase of 29% on the year before. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net profit of NOK 1.5bn, and the EBITDA margin stood at 68.8%.
At the end of 2025, equity financed 89.6% of the balance sheet, and current assets covered short-term debt 9 times.
Financials
Revenue
NOK millionsEBITDA
NOK millionsIncome statement
NOK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2,606,627 | 2,017,487 | 2,179,986 | 1,568,977 | 1,264,115 |
| Staff expenses | -395,440 | -370,833 | -295,418 | -277,903 | -252,634 |
| EBITDA | 1,792,909 | 1,203,062 | 1,362,916 | 878,779 | 616,316 |
| Depreciation & amort. | -48,510 | -47,022 | -41,725 | -38,508 | -37,019 |
| EBIT | 1,744,399 | 1,156,040 | 1,321,191 | 840,271 | 579,297 |
| Net financials | 131,985 | 71,325 | 59,846 | -67,615 | -35,277 |
| Profit before tax | 1,876,384 | 1,227,365 | 1,381,036 | 772,656 | 544,020 |
| Tax | 417,733 | 278,362 | 303,022 | 186,711 | 121,465 |
| Net profit | 1,458,651 | 949,003 | 1,078,014 | 585,945 | 422,555 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
NOK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 6,615,770 | 4,993,092 | 3,995,280 | 2,834,967 | 2,149,577 |
| Equity | 5,924,458 | 4,465,808 | 3,521,526 | 2,443,513 | 1,863,022 |
| Long-term debt | 0 | 43,134 | 8,143 | 883 | 9,770 |
| Short-term debt | 691,312 | 484,151 | 465,611 | 390,571 | 276,785 |
| Total debt | 691,312 | 527,285 | 473,754 | 391,454 | 286,555 |
Financial ratios
5-year trendEBITDA margin
68.8 %
20212025
Equity ratio
89.6 %
Very strongAmong the 20% highest rated companies in the industry
20212025
Return on equity
24.6 %
StrongAmong the 40% highest rated companies in the industry
20212025
Net profit margin
56.0 %
Very strongAmong the 10% highest rated companies in the industry
20212025
Asset turnover
0.39×
WeakAmong the 40% lowest rated companies in the industry
20212025
Debt / equity
0.12×
Very strongAmong the 20% highest rated companies in the industry
20212025
Sector performance
28 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Gross marginStrong
Among the 30% highest rated companies in the industry
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginVery strong
Among the 10% highest rated companies in the industry
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginVery strong
Among the 10% highest rated companies in the industry
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Strong
Among the 40% highest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Very strong
Among the 20% highest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Strong
Among the 40% highest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Very strong
Among the 20% highest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioVery strong
Among the 10% highest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioVery strong
Among the 20% highest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioVery strong
Among the 20% highest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioVery weak
Among the 10% lowest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityStrong
Among the 40% highest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalVery strong
Among the 20% highest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioAverage
Around the average of companies in the same industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioVery strong
Among the 20% highest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioVery strong
Among the 20% highest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityVery strong
Among the 20% highest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityVery strong
Among the 20% highest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtVery strong
Among the 10% highest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtVery strong
Among the 10% highest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageVery strong
Among the 10% highest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtStrong
Among the 40% highest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginVery strong
Among the 20% highest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverWeak
Among the 40% lowest rated companies in the industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverStrong
Among the 30% highest rated companies in the industry
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Equity to contributed capitalVery strong
Among the 10% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityVery strong
Among the 20% highest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtWeak
Among the 30% lowest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Annual reports & filings
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
BM Chief Executive Officer | Chief Executive Officer | 2021 |
BF Deputy Member | Deputy Member | 2016 |
Former (2)
EM Deputy Member | Deputy Member | 2016 – 2021 |
MK Chief Executive Officer | Chief Executive Officer | 2004 – 2021 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
NA Board of Directors | Board of Directors | 2016 |
SH Board of Directors | Board of Directors | 2016 |
BB Chairman | Chairman | 2021 |
MR Board of Directors | Board of Directors | 2016 |
Former (2)
AB Board of Directors | Board of Directors | 2016 – 2021 |
CJ Chairman | Chairman | 2016 – 2021 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
Zoetis B.V. | Company | 100% | 100% | 2025 |
| Company | 100% | 100% | 2020 | |
Zoetis Netherlands 3 B.V. | Company | 100% | 100% | 2021 |
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Zoetis B.V.
Pharmaq AS Board network connections
Board members of Pharmaq AS also hold positions in 36 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Morten Kristoffer Nordstad | Chief Executive Officer | 21 companiesMany roles |
| Nils Arne Grønlie | Board of Directors | 8 companiesMany roles |
| Bernt Martinsen | Chief Executive Officer | 2 companies |
| Børre Furulund | Deputy Member | 2 companies |
| Elin Marie Aksnes | Deputy Member | 1 company |
| Ben Backmann | Chairman | 1 company |
| Marit Rode | Board of Directors | 1 company |
Frequently asked questions
What is the Org number of Pharmaq AS?
Pharmaq AS is registered with Brønnøysundsregistrene under Org 886953402.
What is the revenue of Pharmaq AS?
Pharmaq AS reported revenue of NOK 2.6bn in 2025.
How many employees does Pharmaq AS have?
Pharmaq AS employs 297 people as of the latest annual report.
Who is the CEO of Pharmaq AS?
Bernt Martinsen is the CEO of Pharmaq AS, in role since 2021.
Who is the chairman of Pharmaq AS?
Ben Backmann chairs the board of Pharmaq AS, in role since 2021.
Where is Pharmaq AS headquartered?
Pharmaq AS's registered address is Industrivegen 50.